Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms ESTEEM-1
- Sponsors Amgen; Celgene Corporation
- 21 Mar 2023 Results From ESTEEM 1 and ESTEEM 2 analyzing efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups, resented at the American Academy of Dermatology annual Meeting 2023
- 01 Nov 2021 Results to develop population pharmacokinetic model and exposure-response models to determine whether Japanese subjects (NCT01988103) with moderate to severe psoriasis display similar plasma drug concentration profiles and a comparable response to apremilast treatment versus non-Japanese (NCT00773734 and NCT01194219), predominantly Caucasian subjects with moderate to severe psoriasis, published in the Journal of Dermatology.
- 25 Apr 2021 Results assessing APR on scalp and nail psoriasis in patients with and without dermatology investigator-reported PsA history in moderate-to-severe psoriasis from ESTEEM 1 & 2 and LIBERATE trials presented at the American Academy of Dermatology Virtual Meeting Experience 2021